Overview

Effect of Xolair on Airway Hyperresponsiveness

Status:
Unknown status

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if Xolair can reduce the abnormal increase in limitation to airflow in patients with asthma in a relatively short time period. Another purpose is to determine if Xolair will decrease the amount of inflammation in the lungs of an asthmatic patient in the same time period.

Phase:

Phase 4

Details

Lead Sponsor:

Creighton University

Collaborator:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal
Omalizumab